200mg

DRUG2 trials

Sponsors

Beijing Chaoyang Hospital, Capital Medical University, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions

Diabetic Neuropathy PeripheralNovel Coronavirus Pneumonia (COVID-19)

Phase 1

Study on Safety, Absorption and Metabolism of SYHA1402 Tablets in Healthy People

CompletedNCT03988413

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Diabetic Neuropathy Peripheral

Start: 2019-08-05End: 2020-01-14Updated: 2020-04-30

Phase 2

A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)

RecruitingChiCTR2000029996

Beijing Chaoyang Hospital, Capital Medical UniversityNovel Coronavirus Pneumonia (COVID-19)

Start: 2020-02-20Updated: 2020-02-25

Related Papers

Safety, Tolerability and Pharmacokinetics of Single-Dose Oral SYHA1402 in Healthy Chinese Subjects.

2023-04-24